Overview
Stephan Rau explained why drugs going off-patent has been a major driver of pharmaceutical industry mergers. “If pharmaceutical companies don’t have new products in their pipeline, they buy them,” Mr. Rau said. “Companies are looking at biotech, at smaller companies, and seeking to buy them or to enter into venture capital-style agreements to secure the rights to products so they can get them into their pipelines.” Read the full article.
